STOK Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Stoke Therapeutics Inc (STOK) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock shows bullish technical indicators, strong analyst support with significant upside potential, and positive sentiment around its lead drug candidate. While financials show a revenue drop, the company is in a growth phase with promising drug development.
The MACD is positive at 0.283, indicating bullish momentum. RSI is neutral at 61.645, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key resistance levels are at 36.34 and 37.788, with support at 33.997 and 31.654. The stock is trading near its resistance levels, suggesting upward potential.
Analysts have raised price targets significantly, with Canaccord and Guggenheim setting targets at $60, citing the potential of zorevunersen as a disease-modifying therapy for Dravet syndrome.
The company is on track with its Phase 3 EMPEROR trial timeline, and recent clinical data reinforces confidence in its lead drug.
Bullish technical indicators support a positive price trend.
Lack of recent news or significant trading trends from hedge funds and insiders.
Financial performance shows a sharp revenue decline in Q4 2025, which may concern some investors.
In Q4 2025, revenue dropped by 93.80% YoY to $1.402M. However, net income improved significantly to -$57.93M (up 452.70% YoY), and EPS increased to -0.98 (up 444.44% YoY). Gross margin remained stable at 100%. The company appears to be in a growth and investment phase, focusing on its lead drug development.
Analysts have a strong positive outlook on STOK. Canaccord raised the price target to $60, citing the $600k/year pricing for zorevunersen and its potential market impact. Guggenheim and Wedbush have also raised targets, highlighting the compelling data package for zorevunersen and its potential as a first disease-modifying therapy for Dravet syndrome.
